IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
about
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulationBortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.Tissue-resident and memory properties of human T-cell and NK-cell subsets.Peptide vaccination therapy: Towards the next generation.Dual Roles of IL-27 in Cancer Biology and Immunotherapy.Differentiation of Diverse Progenies of Memory T Cells from Naïve CD8(+) T Cell Precursors.Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect.Redirection to the bone marrow improves T cell persistence and antitumor functions.IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study.Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization.Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions
P2860
Q37655345-DC7DD133-037A-4E2A-A090-F94C5FE38277Q37702765-6C7DDDA7-A5EC-4C9B-BD9C-006BAF021871Q38714915-236A4971-F5CE-44B6-BC82-C0849C778537Q38753973-1D243F67-D549-4F09-B777-3CC8820B1785Q38777005-27649E3C-CAE0-40AF-8C69-0A19C0CC83F1Q38901419-0D639C44-EF86-4D27-B406-DDBD0B593224Q38902336-521D8519-ED20-44CF-89A8-C51BE3A353D6Q39158943-B332CC93-EE50-4693-9FD9-070A06FF3D78Q39243959-1B5824E0-FE05-40B9-8F1F-87E392B775D4Q50034163-D41EC291-4849-43E2-B211-970AD5AD7A58Q50130502-08A433A2-E3EC-4FA4-AB56-32A56031A087Q50534081-9522EF30-FE5D-4ADE-9FBF-BF442F7BB64EQ50644902-6A1954CE-74CE-45B6-BB84-CDF7EDA2B88DQ53099887-72266B8A-2987-46A7-AB58-9979FDE093BAQ55009499-BFDC51E5-3F6C-4627-BD9A-5975E14A234BQ59132180-9D39AD45-535C-405A-A30D-49DBC47F1F76
P2860
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@ast
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@en
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@nl
type
label
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@ast
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@en
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@nl
prefLabel
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@ast
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@en
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@nl
P2093
P2860
P1433
P1476
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
@en
P2093
Enrico Lugli
Karolina Pilipow
Mario Roederer
Thomas A Waldmann
P2860
P304
P356
10.1158/0008-5472.CAN-15-1498
P407
P577
2015-12-15T00:00:00Z